Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Nishio, Makoto; Barlési, Fabrice; West, Howard; Ball, S.; Bordoni, Rodolfo; Cobo, Manuel; Dubray Longeras, Pascale; H. Goldschmidt, Jerome; Novello, Silvia; Orlandi, Francesco; E. Sanborn, Rachel; Szalai, Zsuzsanna; Ursol, G.; Mendus, Diana; Wang, Lijia; Wen, Xiaohui; L. McCleland, Mark; Hoang, Tien; Phan, See; A. Socinski, Mark

doi:10.1016/j.jtho.2020.11.025

Public

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Published in Journal of Thoracic Oncology • Dec 16, 2020

Authors:

Makoto Nishio

Fabrice Barlési

Howard West

Abstract

INTRODUCTION: We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. METHODS: Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alter...

Subject

Pemetrexed

Medicine

Atezolizumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!